Department of Neurology, Faculty of Medicine and Dentistry, Palacky University in Olomouc, University Hospital Olomouc, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic.
J Neural Transm (Vienna). 2012 Mar;119(3):353-62. doi: 10.1007/s00702-011-0708-4. Epub 2011 Sep 4.
Parkinson's disease (PD) is a neurodegenerative disorder with highly heterogeneous clinical manifestations. This fact has prompted many attempts to divide PD patients into clinical subgroups. This could lead to a better recognition of pathogenesis, improving targeted treatment and the prognosis of PD patients. The aim of the present study was to obtain cerebrospinal fluid (CSF) samples in PD patients and to search for a relationship between neurodegenerative CSF markers (tau protein, beta-amyloid(1-42) and index tau protein/beta-amyloid(1-42)) and the clinical subtypes. PD patients were divided into three subgroups: early disease onset (EDO), tremor-dominant PD (TD-PD), and non-tremor dominant PD (NT-PD) according to the previously published classification. Neurodegenerative markers in the CSF were assessed in these three groups of patients suffering from PD (EDO-17, TD-15, NT-16 patients) and in a control group (CG) of 19 patients suffering from non-degenerative neurological diseases and 18 patients with Alzheimer's disease (AD). The NT-PD patients were found to have significantly higher levels of CSF tau protein and index tau/beta than the control subjects and other Parkinsonian subgroups, but no significant differences in these markers were found between AD and NT-PD patients. In the context of more rapid clinical progression and more pronounced neuropathological changes in the NT-PD patient group, our results corroborate the opinion that CSF level of tau protein may be regarded as a potential laboratory marker of the presence and severity of neurodegeneration.
帕金森病（PD）是一种具有高度异质性临床表现的神经退行性疾病。这一事实促使许多人试图将 PD 患者分为临床亚组。这可能导致更好地认识发病机制，改善针对 PD 患者的靶向治疗和预后。本研究的目的是从 PD 患者中获取脑脊液（CSF）样本，并寻找神经退行性 CSF 标志物（tau 蛋白、β-淀粉样蛋白（1-42）和 tau 蛋白/β-淀粉样蛋白（1-42）指数）与临床亚型之间的关系。根据先前发表的分类，将 PD 患者分为三组：早期发病（EDO）、震颤为主的 PD（TD-PD）和非震颤为主的 PD（NT-PD）。评估了这三组 PD 患者（EDO-17、TD-15、NT-16 患者）和 19 名患有非神经退行性疾病和 18 名患有阿尔茨海默病（AD）的对照组（CG）患者的 CSF 中神经退行性标志物。与对照组和其他帕金森亚组相比，NT-PD 患者的 CSF tau 蛋白和 tau 蛋白/β 指数明显升高，但 AD 和 NT-PD 患者之间这些标志物无显著差异。在 NT-PD 患者组中，临床进展更快，神经病理学变化更明显，我们的结果证实了 CSF 中 tau 蛋白水平可能被视为神经退行性变存在和严重程度的潜在实验室标志物的观点。
